A Phase 3 interventional study of ZX008 (Fenfluramine Hydrochloride) in Dravet Syndrome, sponsored by Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc.. Completed at 67 sites in 12 countries. Open to participants aged 2 Years to 35 Years. Per ClinicalTrials.gov, last updated 2025-07-14.
Sponsored by Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. (part of UCB S.A.) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing fenfluramine in Epilepsies, Myoclonic — 2 open to participants now, 2 under way, none of them phase 3. Fenfluramine · Epilepsies, Myoclonic.
Among the 11 studies testing fenfluramine in Epilepsies, Myoclonic, this one is the 2nd largest by enrollment, is one of 2 that started in 2016, is one of 7 in phase 3, and was the 2nd registered.
92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.
Browse Epilepsies, Myoclonic studies →2 of the 11 studies testing fenfluramine in Epilepsies, Myoclonic are open now, in 1 country. Recruiting first, the newest first:
The University of Texas Health Science Center, Houston · Sites in United States
Ages 16+
University of Colorado, Denver · Sites in United States
Ages 12 mo–24 mo
By country, each count listing its studies:
Fenfluramine: first FDA approval 2020 (FINTEPLA), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.
This study: 2 Years to 35 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2016; this study’s year is marked. 2 started in 2016.
This study's enrollment of 375 is above the median of 31 across 56 interventional studies indexed under Epilepsies, Myoclonic.
Median enrollment 25 across the 11 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 11 have an industry lead sponsor. The 7 most frequent:
This study is registered under Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc., one of the names counted as UCB S.A.. Under that name alone:
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 6 completed or terminated interventional studies of FDA-regulated products, 5 (83%) have results posted.
UCB S.A. has 8 studies filed under Epilepsies, Myoclonic — fewer than ten, so there is no comparison to draw.
2 of the studies testing fenfluramine in Epilepsies, Myoclonic that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06598449University of Colorado, DenverAssessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age | 2026-12 |
| NCT07112365The University of Texas Health Science Center, HoustonThe FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project | 2027-09-30 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies testing fenfluramine in Epilepsies, Myoclonic, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an international, multicenter, open-label, long-term safety study of ZX008 in subjects with Dravet syndrome.
This is an international, multicenter, open-label, long-term safety study of ZX008 in pediatric and young adult subjects with Dravet syndrome who participated in one of the core studies (ZX008-1501 and ZX008-1502) and are candidates for continuous treatment for an extended period of time. This trial will consist of a 36-month Open-Label Extension (OLE) Treatment Period and a 2-week Post-Dosing Period.
Key Inclusion Criteria:
Key Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
Drug: ZX008 (Fenfluramine Hydrochloride)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Open-label Extension (OLE) Treatment Period
Treatment-emergent adverse events (TEAE) were defined as any AEs that based on start date information occurs after the first intake of study treatment.
Time frame: From Day 1 to End of OLE Treatment Period - End of Study (EOS) Visit (Month 42)
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the OLE Treatment Period
A TEAE was defined as any AE that based on start date information occurs after the first intake of study treatment. Percentage of participants with TEAEs leading to withdrawal from IMP during OLE Treatment Period were reported.
Time frame: From Day 1 to End of OLE Treatment Period - EOS Visit (Month 42)
Percentage of Participants With Serious Treatment-emergent Adverse Events (TEAEs) During the OLE Treatment Period
Serious Adverse event (SAE) was defined as any untoward medical occurrence that at any dose: • results in death, • is life-threatening threatening, • results in initial inpatient hospitalization or prolongation of hospitalization, •results in persistent or significant disability or incapacity, • results in a congenital anomaly/birth defect, • results in any medically significant event that did not meet any of the other 5 SAE criteria, but which was judged by a physician to potentially jeopardize the participant or require medical or surgical intervention to prevent one of the above outcomes listed as an SAE criterion.
Time frame: From Day 1 to End of OLE Treatment Period - EOS Visit (Month 42)
Change From Baseline (Core) in Convulsive Seizure Frequency Per 28 Days From Day 1 to End of Study (EOS) Visit (Month 42) in the OLE Treatment Period
Baseline (Core) was defined as Baseline prior to double-blind treatment in the core studies (ZX008-1501/ZX008-1502, and ZX008-1504 Cohort 2). Participants in 1504- Cohort 1 and de novo participants (who entered 1503 without having been in any of the core studies) did not have a Baseline (Core), and were not included in the analysis of this outcome measure. The total number of convulsive seizures from Day 1 to EOS was divided by the total number of days from Day 1 to EOS with nonmissing diary data and the result was then multiplied by 28 to get a 28-day convulsive seizure frequency (CSF). The change from Baseline for any individual participant was calculated by subtracting the Baseline (Core) from the post-baseline value. Monthly (28 day) CSF was based on electronic diary data obtained for each participant.
Time frame: From Day 1 to End of OLE Treatment Period (EOS Visit - up to Month 42), compared to Baseline (Core)
Change From Baseline (Core) in Convulsive Seizure Frequency Per 28 Days From Month 2 to EOS (Month 42) in the OLE Treatment Period
Baseline (Core) was defined as Baseline prior to double-blind treatment in the core studies. Participants in 1504-Cohort 1 and de novo participants did not have a Baseline (Core), and were not included in the analysis of this outcome measure. The total number of convulsive seizures from Month 2 to EOS was divided by the total number of days from Month 2 to EOS with nonmissing diary data and the result was then multiplied by 28 to get a 28-day CSF. The change from Baseline for any individual participant was calculated by subtracting the Baseline (Core) from the post-baseline value. Monthly (28 day) CSF was based on electronic diary data obtained for each participant.
Time frame: From Month 2 to End of OLE Treatment Period (EOS Visit - up to Month 42), compared to Baseline (Core)
Convulsive Seizure Frequency (CSF) Per 28 Days During the OLE Treatment Period (to Month 36)
Monthly (28 day) CSF was based on electronic diary data obtained for each participant. The total number of convulsive seizures in the ith interval (CSF in OLE, where, i=1, 2, 3, … , 14 ) was divided by the total number of days in the ith interval with nonmissing diary data and the result was then multiplied by 28 to get a 28-day CSF of OLE.
Time frame: At Month 1, Month 2, Month 3, Month 4-6, Month 7-9, Month 10-12, Month 13-15, Month 16-18, Month 19-21, Month 22-24, Month 25-27, Month 28-30, Month 31-33, and Month 34-36
Convulsive Seizure Frequency (CSF) by Mean Daily Dose During the Overall OLE Treatment Period
Convulsive seizure frequency over time, reported as per 28 days was analyzed by the actual dose administered. Participants were grouped into low (0.2 to \<0.4 mg/kg), medium (0.4 to \<0.6 mg/kg), and high dose (\>0.6 mg/kg) groups depending on their mean daily doses of ZX008 during the OLE Treatment period. For each participant, the seizure frequency per 28 days was calculated as the number of seizures recorded during the period, divided by the number of days in the period and multiplied by 28. The convulsive seizure frequency was calculated from all available data collected.
Time frame: From Day 1 to End of OLE Treatment Period - End of Study (EOS) Visit (Month 42)
Percentage of Participants With Changes in Antiepileptic Drug (AED) Medications During First 6 Months of OLE Treatment Period
Participants in the study were required to be on stable background therapy for the first 6 months of treatment, after which background AEDs could be reduced or withdrawn so long as one background AED remained. The percentage of participants who had changes in dose or type of concomitant AED medications during the first, second, third, fourth, fifth, and sixth months were analyzed and reported.
Time frame: At Month 1, 2, 3, 4 , 5, and 6 of OLE Treatment Period
The study started to enroll participants in Jun 2016 and concluded in Jan 2023. Participants who completed 14 weeks treatment in any of the core studies ZX008-1501/ZX008-1502 (NCT02682927), or ZX008-1504 (NCT02926898) Cohort 2, or completed ZX008-1504 Cohort 1 study, and de novo participants were eligible to participate in this study.
| Milestone | Not Treated | Any ZX008 Open Label Dose |
|---|---|---|
| Started | 1 | 374 |
| Completed | 0 | 374 |
| Not completed | 1 | 0 |
| Withdrew: Other | 1 | 0 |
| Milestone | Not Treated | Any ZX008 Open Label Dose |
|---|---|---|
| Started | 0 | 374 |
| Completed | 0 | 49 |
| Not completed | 0 | 325 |
| Withdrew: Adverse event | 0 | 11 |
| Withdrew: Death | 0 | 3 |
| Withdrew: Family decision | 0 | 1 |
| Withdrew: Ip approved and subject moved to commercial drug | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 48 |
| Withdrew: Non-compliance with e-diary | 0 | 1 |
| Withdrew: Physician decision | 0 | 2 |
| Withdrew: Subject has transitioned to study 1900 ole study | 0 | 225 |
| Withdrew: Subject needed to take prohibited medication | 0 | 1 |
| Withdrew: Subject transferred to direct access programme | 0 | 1 |
| Withdrew: Switching to commercially available drug | 0 | 11 |
| Withdrew: Transitioned to commercial supply of medication | 0 | 1 |
| Withdrew: Withdrawal by caregiver | 0 | 1 |
| Withdrew: Withdrawal by sponsor due to lack of compliance | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 16 |
| Withdrew: Reason unknown | 0 | 1 |
Treatment-emergent adverse events (TEAE) were defined as any AEs that based on start date information occurs after the first intake of study treatment.
| percentage of participants | Any ZX008 Open Label Dose |
|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) During the Open-label Extension (OLE) Treatment Period | 98.1 |
A TEAE was defined as any AE that based on start date information occurs after the first intake of study treatment. Percentage of participants with TEAEs leading to withdrawal from IMP during OLE Treatment Period were reported.
| percentage of participants | Any ZX008 Open Label Dose |
|---|---|
| Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) Leading to Withdrawal From Investigational Medicinal Product (IMP) During the OLE Treatment Period | 3.5 |
Serious Adverse event (SAE) was defined as any untoward medical occurrence that at any dose: • results in death, • is life-threatening threatening, • results in initial inpatient hospitalization or prolongation of hospitalization, •results in persistent or significant disability or incapacity, • results in a congenital anomaly/birth defect, • results in any medically significant event that did not meet any of the other 5 SAE criteria, but which was judged by a physician to potentially jeopardize the participant or require medical or surgical intervention to prevent one of the above outcomes listed as an SAE criterion.
| percentage of participants | Any ZX008 Open Label Dose |
|---|---|
| Percentage of Participants With Serious Treatment-emergent Adverse Events (TEAEs) During the OLE Treatment Period | 26.5 |
Baseline (Core) was defined as Baseline prior to double-blind treatment in the core studies (ZX008-1501/ZX008-1502, and ZX008-1504 Cohort 2). Participants in 1504- Cohort 1 and de novo participants (who entered 1503 without having been in any of the core studies) did not have a Baseline (Core), and were not included in the analysis of this outcome measure. The total number of convulsive seizures from Day 1 to EOS was divided by the total number of days from Day 1 to EOS with nonmissing diary data and the result was then multiplied by 28 to get a 28-day convulsive seizure frequency (CSF). The change from Baseline for any individual participant was calculated by subtracting the Baseline (Core) from the post-baseline value. Monthly (28 day) CSF was based on electronic diary data obtained for each participant.
| seizure frequency per 28 days | Any ZX008 Open Label Dose |
|---|---|
| Change From Baseline (Core) in Convulsive Seizure Frequency Per 28 Days From Day 1 to End of Study (EOS) Visit (Month 42) in the OLE Treatment Period | -6.67 (-1757.8 to 751.3) |
Baseline (Core) was defined as Baseline prior to double-blind treatment in the core studies. Participants in 1504-Cohort 1 and de novo participants did not have a Baseline (Core), and were not included in the analysis of this outcome measure. The total number of convulsive seizures from Month 2 to EOS was divided by the total number of days from Month 2 to EOS with nonmissing diary data and the result was then multiplied by 28 to get a 28-day CSF. The change from Baseline for any individual participant was calculated by subtracting the Baseline (Core) from the post-baseline value. Monthly (28 day) CSF was based on electronic diary data obtained for each participant.
| seizure frequency per 28 days | Any ZX008 Open Label Dose |
|---|---|
| Change From Baseline (Core) in Convulsive Seizure Frequency Per 28 Days From Month 2 to EOS (Month 42) in the OLE Treatment Period | -7.04 (-1986.9 to 816.4) |
Monthly (28 day) CSF was based on electronic diary data obtained for each participant. The total number of convulsive seizures in the ith interval (CSF in OLE, where, i=1, 2, 3, … , 14 ) was divided by the total number of days in the ith interval with nonmissing diary data and the result was then multiplied by 28 to get a 28-day CSF of OLE.
| seizure frequency per 28 days | Any ZX008 Open Label Dose |
|---|---|
| Month 1 | 6.53 (0.0 to 4876.9) |
| Month 2 | 4.67 (0.0 to 3392.7) |
| Month 3 | 4.67 (0.0 to 2593.7) |
| Month 4-6 | 4.36 (0.0 to 1725.5) |
| Month 7-9 | 3.82 (0.0 to 310.8) |
| Month 10-12 | 4.04 (0.0 to 362.4) |
| Month 13-15 | 3.11 (0.0 to 215.0) |
| Month 16-18 | 3.42 (0.0 to 243.3) |
| Month 19-21 | 3.42 (0.0 to 372.4) |
| Month 22-24 | 2.80 (0.0 to 489.5) |
| Month 25-27 | 2.80 (0.0 to 747.3) |
| Month 28-30 | 2.80 (0.0 to 242.5) |
| Month 31-33 | 3.21 (0.0 to 224.0) |
| Month 34-36 | 2.74 (0.0 to 56.0) |
Convulsive seizure frequency over time, reported as per 28 days was analyzed by the actual dose administered. Participants were grouped into low (0.2 to \<0.4 mg/kg), medium (0.4 to \<0.6 mg/kg), and high dose (\>0.6 mg/kg) groups depending on their mean daily doses of ZX008 during the OLE Treatment period. For each participant, the seizure frequency per 28 days was calculated as the number of seizures recorded during the period, divided by the number of days in the period and multiplied by 28. The convulsive seizure frequency was calculated from all available data collected.
| seizure frequency per 28 days | Any ZX008 Open Label Dose |
|---|---|
| ZX008 Low Dose (0 - <0.4 mg/kg/day) | 3.94 (0.0 to 2215.3) |
| ZX008 Medium Dose (0.4 - <0.6 mg/kg/day) | 4.80 (0.0 to 113.6) |
| ZX008 High Dose (>=0.6 mg/kg/day) | 6.00 (0.1 to 942.8) |
Participants in the study were required to be on stable background therapy for the first 6 months of treatment, after which background AEDs could be reduced or withdrawn so long as one background AED remained. The percentage of participants who had changes in dose or type of concomitant AED medications during the first, second, third, fourth, fifth, and sixth months were analyzed and reported.
| percentage of participants | Any ZX008 Open Label Dose |
|---|---|
| OLE Month 1 | 5.2 |
| OLE Month 2 | 7.1 |
| OLE Month 3 | 7.4 |
| OLE Month 4 | 8.3 |
| OLE Month 5 | 6.8 |
| OLE Month 6 | 9.6 |
Collected over From Day 1 up to 42 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Any ZX008 Open Label Dose | 3/374 (0.8%) | 99/374 (26.5%) | 342/374 (91.4%) |
| Event | Any ZX008 Open Label Dose |
|---|---|
| SeizureNervous system disorders | 21/374 |
| Status epilepticusNervous system disorders | 15/374 |
| PneumoniaInfections and infestations | 12/374 |
| InfluenzaInfections and infestations | 7/374 |
| Seizure clusterNervous system disorders | 6/374 |
| Viral infectionInfections and infestations | 5/374 |
| Change in seizure presentationNervous system disorders | 5/374 |
| Sudden unexplained death in epilepsyGeneral disorders | 3/374 |
| GastroenteritisInfections and infestations | 3/374 |
| Lower respiratory tract infectionInfections and infestations | 3/374 |
| Event | Any ZX008 Open Label Dose |
|---|---|
| PyrexiaGeneral disorders | 112/374 |
| NasopharyngitisInfections and infestations | 104/374 |
| Decreased appetiteMetabolism and nutrition disorders | 100/374 |
| Blood glucose decreasedInvestigations | 88/374 |
| DiarrhoeaGastrointestinal disorders | 73/374 |
| Echocardiogram abnormalInvestigations | 67/374 |
| Upper respiratory tract infectionInfections and infestations | 65/374 |
| SeizureNervous system disorders | 46/374 |
| InfluenzaInfections and infestations | 45/374 |
| VomitingGastrointestinal disorders | 39/374 |
Baseline characteristics refers to the Safety (SAF) population which included all enrolled participants who received at least one dose of ZX008 during the open label extension (OLE). As pre-specified in the SAP, participant Demographics and Baseline Characteristics were summarized for the safety population.
| Age, Continuous(years) | Any ZX008 Open Label Dose |
|---|---|
| Mean | 10.3 ± 6.12 |
| Age, Customized(Participants) | Any ZX008 Open Label Dose |
|---|---|
| <6 years | 92 |
| 6-18 years | 250 |
| >18 years | 32 |
| Sex: Female, Male(Participants) | Any ZX008 Open Label Dose |
|---|---|
| Female | 172 |
| Male | 202 |
| Race/Ethnicity, Customized(Participants) | Any ZX008 Open Label Dose |
|---|---|
| White | 275 |
| Black or African American | 5 |
| Asian | 31 |
| American Indian or Alaska Native | 2 |
| Other | 17 |
| Not Reported | 44 |
| Race/Ethnicity, Customized(Participants) | Any ZX008 Open Label Dose |
|---|---|
| Hispanic or Latino | 44 |
| Not Hispanic or Latino | 267 |
| Not Reported | 55 |
| Unknown | 8 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe, or global development is discontinued, and 18 months after trial completion. Investigators may request access to anonymized individual patient-level data and redacted trial documents which may include: analysis-ready datasets, study protocol, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a prespecified time, typically 12 months, on a password protected portal. This plan may change if the risk of re-identifying trial participants is determined to be too high after the trial is completed; in this case and to protect participants, individual patient-level data would not be made available.
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Data from this trial may be requested by qualified researchers six months after product approval in the US and/or Europe or global development is discontinued, and 18 months after trial completion.
Access criteria: Qualified researchers may request access to anonymized IPD and redacted study documents which may include: raw datasets, analysis-ready datasets, study protocol, blank case report form, annotated case report form, statistical analysis plan, dataset specifications, and clinical study report. Prior to use of the data, proposals need to be approved by an independent review panel at www.Vivli.org and a signed data sharing agreement will need to be executed. All documents are available in English only, for a pre-specified time, typically 12 months, on a password protected portal.
Data sharing details ↗ · www.vivli.org
Ran from Jun 2016 to primary completion in Jan 2023, 79 months.
Results were first posted in Sep 2023, 7 months after primary completion.
Of 15 phase 3 interventional studies under Epilepsies, Myoclonic, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 72. This study's 79 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fenfluramine
Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. →